KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Operating Leases (2019 - 2025)

Exact Sciences (EXAS) has disclosed Operating Leases for 7 consecutive years, with $161.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 3.06% to $161.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $161.9 million, a 3.06% increase, with the full-year FY2025 number at $161.9 million, up 3.06% from a year prior.
  • Operating Leases was $161.9 million for Q4 2025 at Exact Sciences, down from $163.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $213.0 million in Q2 2022 to a low of $157.1 million in Q4 2024.
  • A 5-year average of $180.6 million and a median of $180.6 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 50.43% in 2021, then fell 20.89% in 2023.
  • Exact Sciences' Operating Leases stood at $182.2 million in 2021, then grew by 15.72% to $210.8 million in 2022, then dropped by 9.68% to $190.4 million in 2023, then fell by 17.49% to $157.1 million in 2024, then rose by 3.06% to $161.9 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Operating Leases are $161.9 million (Q4 2025), $163.9 million (Q3 2025), and $166.0 million (Q2 2025).